Clinical trials for Retinitis pigmentosa
41 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGN/ANCT07292987Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts · PI: Isabelle Audo, Pr
- RECRUITINGN/ANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind · PI: Marianna Weener, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPhase 2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics · PI: None None
- RECRUITINGPhase 2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc. · PI: Doron Hickey, MBChB
- RECRUITINGPhase 2NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)jCyte, Inc · PI: Henry Klassen, MD, PhD
- RECRUITINGNCT06982417InsightRP2 RegistryUniversity of Göttingen
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07341919Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal DiseasesRubens Camargo Siqueira · PI: Rubens C Siqueira, MD,PhD
- RECRUITINGPhase 2NCT06627179Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneLaboratoires Thea
- RECRUITINGPHASE1, PHASE2NCT06787482Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and DystrophiesAce Cells Lab Limited · PI: Dr. Passant Sayed Saif, PhD ophthalmology
- ACTIVE NOT RECRUITINGPhase 2NCT06646289A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)Janssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- ACTIVE NOT RECRUITINGNCT06517940A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)Sumitomo Pharma America, Inc.
- ENROLLING BY INVITATIONN/ANCT07088705Subthreshold Micropulse Laser Therapy (SML) in Retinitis PigmentosaMarta P. Wiącek
- RECRUITINGPHASE1, PHASE2NCT06242379Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis PigmentosaMahidol University · PI: Laongsri Atchaneeyasakul, Professor
- RECRUITINGPHASE1, PHASE2NCT06492850Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis PigmentosaFrontera Therapeutics · PI: Ruifang Sui
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT04850118A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPBeacon Therapeutics · PI: Carrie Reichley
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07348588Intravitreal Adalimumab in Inherited and Degenerative Retinal DiseasesCentro de Pesquisa Rubens Siqueira
- ENROLLING BY INVITATIONPhase 2NCT06275620A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPhase 3NCT05537220Oral N-acetylcysteine for Retinitis PigmentosaJohns Hopkins University · PI: Peter A Campochiaro, MD
- RECRUITINGN/ANCT05853107Pilot Study of AuTNA IEye & ENT Hospital of Fudan University · PI: Chunhui Jiang
- RECRUITINGEarly Phase 1NCT05874310Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis PigmentosaFrontera Therapeutics · PI: Gezhi Xu
- ACTIVE NOT RECRUITINGNCT05573984Natural History of PRPF31 Mutation-Associated Retinal DystrophyPYC Therapeutics · PI: Sreenivasu Mudumba, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT04284293CNS10-NPC for the Treatment of RPCedars-Sinai Medical Center · PI: David Liao, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT06333249A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)Beacon Therapeutics
- ACTIVE NOT RECRUITINGNCT04805658Natural History Study of Retinitis Pigmentosa Type 11Oslo University Hospital · PI: Josephine P Holtan, MD, PHD
- ACTIVE NOT RECRUITINGPhase 3NCT04794101Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT045171494D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)4D Molecular Therapeutics · PI: Schonmei Lee, MD
- ACTIVE NOT RECRUITINGNCT04127006Rate of Progression in EYS Related Retinal DegenerationJaeb Center for Health Research · PI: Mark Pennesi, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT04278131BS01 in Patients With Retinitis PigmentosaBionic Sight LLC · PI: Sheila Nirenberg, PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04123626A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO GeneProQR Therapeutics · PI: ProQR Medical Monitor
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04611503PDE6A Gene Therapy for Retinitis PigmentosaSTZ eyetrial · PI: Dominik Fischer, Prof.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03963154Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic MutationCentre d'Etude des Cellules Souches · PI: Stéphane BERTIN, MD
- RECRUITINGNCT04639635CNGB1 and Allied DisordersColumbia University · PI: Stephen Tsang, MD, PhD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03374657A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03316560Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsBeacon Therapeutics
- RECRUITINGN/ANCT03635645Experimental and Clinical Studies of Retinal StimulationUniversity of Michigan · PI: James Weiland
- ACTIVE NOT RECRUITINGNCT03146078Rate of Progression in USH2A-related Retinal DegenerationJaeb Center for Health Research · PI: Jacque Duncan, MD
- ACTIVE NOT RECRUITINGN/ANCT02086890Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis PigmentosaNova Southeastern University · PI: Kenneth R Seger, OD, MSc
- RECRUITINGNCT00254605Retinal Imaging in Patients With Inherited Retinal DegenerationsUniversity of California, San Francisco · PI: Jacque L. Duncan, M.D.